Literature DB >> 25374342

Anti-hepatoma activity of a novel compound glaucocalyxin H in vivo and in vitro.

Guangfan Hai1, Chong Zhang, Yanlong Jia, Suping Bai, Jinfen Han, Lanqing Guo, Taizhen Cui, Bingxuan Niu, Feng Huang, Yu Song.   

Abstract

Glaucocalyxin H (GLH) is a new compound isolated from a traditional Chinese medical herb Isodon japonica var. glaucocalyx which has been used for folk medicine. This study was carried out for the first time to investigate the potential role of GLH in anti-hepatoma activity and underlying mechanisms in it. GLH could inhibit the growth of tumor in mice and induce HepG2 cells to death as assessed by the tumor reduction assay, toxic assay, morphological change, and survival rate assay. Many antitumor drugs originated from plants could inhibit the growth of tumor by inducing cells to apoptosis. The morphological changes of HepG2 cells treated with different concentrations of GLH under fluorescence and electron microscope and apoptotic rates were detected to verify its effect on apoptosis. As shown in the study, GLH could induce HepG2 cells to apoptosis in a dose-dependent manner. Bcl2 and Bax proteins played important roles in apoptosis and the disequilibrium between Bcl2 and Bax might result in apoptosis. The expression of Bax protein was upregulated and Bcl2 protein was downregulated in HepG2 cells treated with GLH assessed by Western blotting, and they were in a dose-dependent manner. Taken together, GLH can inhibit the growth of hepatoma cells in vivo and in vitro by inducing cell apoptosis due to the decreased Bcl2 and increased Bax proteins suggesting that GLH could be a potential candidate as an anti-hepatoma agent for the therapeutic treatment of hepatoma.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25374342      PMCID: PMC4444621          DOI: 10.1208/s12249-014-0227-3

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  16 in total

1.  Antitumor activity of the components of Isodon trichocarpus and related plants.

Authors:  T ARAI; Y KOYAMA; T SUENAGA; T MORITA
Journal:  J Antibiot (Tokyo)       Date:  1963-05       Impact factor: 2.649

Review 2.  Anti-influenza agents from Traditional Chinese Medicine.

Authors:  Hu Ge; Yi-Fei Wang; Jun Xu; Qiong Gu; Hai-Bo Liu; Pei-Gen Xiao; Jiaju Zhou; Yanhuai Liu; Zirong Yang; Hua Su
Journal:  Nat Prod Rep       Date:  2010-10-13       Impact factor: 13.423

Review 3.  Mitochondrial outer membrane permeabilization during apoptosis: the innocent bystander scenario.

Authors:  J E Chipuk; L Bouchier-Hayes; D R Green
Journal:  Cell Death Differ       Date:  2006-05-19       Impact factor: 15.828

4.  Antitumor activity of the Isodon diterpenoids: structural requirements for the activity.

Authors:  E Fujita; Y Nagao; M Node; K Kaneko; S Nakazawa; H Kuroda
Journal:  Experientia       Date:  1976-02-15

5.  [Effect of glaucocalyxin A on level of Th1/Th2 type cytokines in mice].

Authors:  Zi-jun Chen; Yun-sen Li; Ji-yan Zhou; Zheng-tao Wang
Journal:  Zhongguo Zhong Yao Za Zhi       Date:  2006-08

Review 6.  The biochemistry of programmed cell death.

Authors:  G Kroemer; P Petit; N Zamzami; J L Vayssière; B Mignotte
Journal:  FASEB J       Date:  1995-10       Impact factor: 5.191

7.  Cytochrome c promotes caspase-9 activation by inducing nucleotide binding to Apaf-1.

Authors:  X Jiang; X Wang
Journal:  J Biol Chem       Date:  2000-10-06       Impact factor: 5.157

8.  Isolation, structural elucidation, and cytotoxicity of three new ent-kaurane diterpenoids from Isodon japonica var. glaucocalyx.

Authors:  Hui-Juan Liang; Yun-Xiao Zhang; Guang-Fan Hai; Su-Ping Bai; Yong-Liang Yuan; Dan-Dan Ye; Nan-Qian Zhou
Journal:  Planta Med       Date:  2012-02-09       Impact factor: 3.352

9.  An ent-kaurane diterpenoid from Isodon japonica var. glaucocalyx.

Authors:  Su-Ping Bai; Guo-Sheng Luo; Xiao-Yi Zhang; Wei Liu
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2009-07-18

10.  The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer.

Authors:  Michael Eichbaum; Christine Mayer; Regina Eickhoff; Esther Bischofs; Gerhard Gebauer; Tanja Fehm; Florian Lenz; Hans-Christian Fricke; Erich Solomayer; Nikos Fersis; Marcus Schmidt; Markus Wallwiener; Andreas Schneeweiss; Christof Sohn
Journal:  BMC Cancer       Date:  2011-10-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.